Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Happy reading, Eloise McLennan Deep Dive editor Contents GLP-1s: Five years that changed metabolic medicine Redesigning obesity trials for a chronic disease era The trust gap: GLP-1s and the new information economy of obesity Designing obesity trials around real lives Building a scalable GLP-1 care model Beyond obesity: How GLP-1s are changing the game for hundreds of diseases GLP-1 pricing and supply: Examining the signals behind the numbers Supercharge your pharma insights: Sign up to pharmaphorum's newsletter for daily updates, weekly roundups, and in-depth analysis across all industry sectors.
MMP/TIMP modulation
While GLP-1 agonists have demonstrated significant benefits for glycemic control and weight management, patients and clinicians must consider potential interactions with thyroid function and the specific considerations relevant to autoimmune thyroid disease
Because of its nature, this is significantly costlier
